<DOC>
	<DOCNO>NCT01965535</DOCNO>
	<brief_summary>This study determine antiviral efficacy sofosbuvir ( SOF ) /ledipasvir ( LDV ) fixed-dose combination ( FDC ) without ribavirin ( RBV ) , evaluate safety tolerability regimen assess review accumulate safety data . Approximately 150 participant genotype 1 HCV infection , previously receive treatment HCV , diagnosis cirrhosis enrol . Participants randomize 1 2 group . Group 1 : SOF/LDV FDC tablet plus placebo match RBV 24 week Group 2 : Delayed treatment group : placebo match SOF/LDV FDC plus placebo match RBV 12 week , follow SOF/LDV FDC daily plus RBV divide daily dose 12 week Randomization 1:1 two group stratify HCV genotype ( 1a , 1b ; mixed genotype 1 result stratify genotype 1a ) , prior HCV therapy treatment response ( never achieve HCV RNA &lt; low limit quantitation ( LLOQ ) , achieve HCV RNA &lt; LLOQ ) .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin Cirrhotic Subjects With Chronic Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Age equal great 18 year , chronic genotype 1 HCV infection HCV RNA ≥ 10,000 IU/mL screen Prior virological failure treatment pegylated interferon ( PEGIFN ) , RBV protease inhibitor follow document prior virology failure treatment PEGIFN + RBV regimen Evidence cirrhosis Screening laboratory value within define threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Current prior history clinical hepatic decompensation Prior exposure approve experimental HCV specific directacting antiviral nonstructural protein ( NS ) 3/4A protease inhibitor History solid organ transplantation , include liver transplant Hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) Chronic use systemic immunosuppressive agent History clinically significant illness medical disorder may interfere subject treatment , assessment compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>